PAM50 Finds New Purpose in the Prostate

0

1. PAM50 biomarker aids in identifying hormone therapy candidates.

2. Focus on Luminal A, Luminal B, Basal-like subtypes in prostate cancer.

3. Validated in a double-blind randomized trial.

4. Can utilize routine biopsies and archival specimens.

5. Collaboration between pathologists and clinicians is vital for success.

6. Next steps include further validation in various prostate cancer settings.